HeartWare: Monitor VAD batteries

Candace Stuart | | Cardiovascular Business | Heart Failure

Heartware International has issued back-to-back warnings about its ventricular assist device (VAD), with the most recent notice involving batteries in the HeartWare Ventricular Assist System.

On April 29, the FDA issued a Class I recall for some HeartWare Ventricular Assist System devices because the locking mechanism in the driveline connector might not properly engage. The failure potentially could stop the pump from pumping and lead to serious adverse events, including death. HeartWare originally reported the problem in December 2013.

HeartWare issued another voluntary correction notice May 1, warning that batteries with the product codes 1650 and 1650-DE might be prone to earlier-than-expected battery depletion. An increase in complaints about the VAD’s battery performance prompted the announcement.

The Framingham, Mass.-based company added that it has not received any reports of deaths related to faulty batteries. Three deaths were reported between Jan. 1, 2011, and March 31, 2014, that potentially involved power source management. In two, both sources of power simultaneously were disconnected and one death was traced to batteries that had exceeded their expected lifetime use.

HeartWare instructed patients and physicians to monitor battery performance for abnormal behavior and review the power source management section in the patient manual. Patients should stop using a suspicious battery and contact their VAD coordinator for a replacement.  

Candace Stuart, Contributor

Related Content

Medtronic using AI to identify more TAVR patients in need
Tirzepatide linked to significant weight loss, ‘impressive’ diabetes prevention after 3 years
Most heart failure patients miss out on guideline-recommended palliative care
CMS updates outpatient reimbursement policy for Barostim device
American Heart Association announces late-breaking research for Scientific Sessions 2024
Impella ECP confirmed to be safe for high-risk PCI—is FDA approval next?

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."